9.4 Herd immunity and vaccine development

Herd Immunity Fundamentals

Herd immunity is a form of indirect protection from infectious disease that kicks in when enough people in a population become immune. Once that threshold is crossed, even people who aren't immune get some protection because the pathogen simply runs out of easy hosts to infect. This is especially critical for people who can't be vaccinated, like newborns, immunocompromised patients, or those with severe allergies to vaccine components.

There are two ways a population builds herd immunity: widespread vaccination or widespread prior infection. Vaccination is the far safer route because natural infection carries the risk of severe disease, complications, and death. When herd immunity is strong enough and sustained over time, it can lead to disease elimination within a region or even global eradication. Smallpox remains the only human disease fully eradicated, and that was achieved through a massive coordinated vaccination campaign.

Calculation of herd immunity threshold

The herd immunity threshold (HIT) depends on how contagious a pathogen is, which is captured by its basic reproductive number ($R_0$). $R_0$ represents the average number of secondary infections one infected person causes in a fully susceptible population.

The formula is:

$HIT = 1 - \frac{1}{R_0}$

What this tells you: the more transmissible a pathogen, the higher the percentage of the population that needs to be immune to stop sustained spread. For example, measles has an $R_0$ of roughly 12–18, which means about 92–95% of the population must be immune. By contrast, seasonal influenza with an $R_0$ around 2 has a threshold closer to 50%.

Several factors influence $R_0$ in practice:

• Pathogen transmissibility (airborne vs. droplet vs. contact spread)
• Population density (crowded cities raise effective transmission)
• Social behaviors (hygiene practices, mask use, cultural norms around physical contact)

Because these factors vary across settings, the effective reproductive number in a real population can differ from the theoretical $R_0$.

Vaccine Development and Considerations

Factors in vaccine development

Developing a vaccine requires matching the right platform to the pathogen's biology and the needs of the target population. Several pathogen characteristics make development harder:

• Antigenic variability means the pathogen's surface proteins keep changing, so the immune system doesn't recognize new strains. Influenza is the classic example, which is why the flu vaccine is reformulated every year.
• Immune evasion mechanisms allow some pathogens to hide from or suppress immune responses, complicating the design of an effective immunogen.
• Genomic stability matters because a stable genome makes it easier to design a vaccine that stays effective over time.

Target population also shapes vaccine design. Vaccines for infants need to work with an immature immune system. Vaccines for immunocompromised individuals often can't use live organisms. Pregnant women require careful safety evaluation since both mother and fetus are at stake.

The major vaccine platforms include:

• Live attenuated (e.g., MMR): uses a weakened form of the pathogen; strong immune response but not safe for immunocompromised patients
• Inactivated (e.g., injectable polio): uses killed pathogen; safer but often requires boosters
• Subunit/recombinant (e.g., hepatitis B): uses specific antigenic proteins; very safe but may need adjuvants to boost immunogenicity
• Nucleic acid (e.g., COVID-19 mRNA vaccines): delivers genetic instructions for the antigen; rapid to develop and adaptable to new variants

Development follows a structured pipeline:

1. Preclinical research: lab studies and animal models to identify candidate antigens and test safety
2. Phase I clinical trial: small group of healthy volunteers; focuses on safety and dosing
3. Phase II clinical trial: larger group; evaluates immunogenicity and refines dosing
4. Phase III clinical trial: thousands of participants; tests efficacy and monitors for rare adverse effects
5. Regulatory approval: agencies (e.g., FDA, EMA) review all data before authorizing use

Ethics of vaccine distribution

Vaccine development and distribution raise several ethical tensions that go beyond the lab bench.

Informed consent is foundational in clinical trials. Participants must understand the risks, and trials should include diverse populations so results are generalizable. Historically, underrepresentation of certain groups in trials has led to gaps in safety and efficacy data.

Equitable access is one of the biggest challenges. Wealthier nations often secure vaccine supplies early, leaving lower-income countries waiting. Initiatives like COVAX were created to pool resources and distribute vaccines more fairly across nations, though implementation has been uneven.

Vaccine hesitancy stems from multiple sources: misinformation (especially on social media), historical distrust in healthcare systems (often rooted in real past abuses), and cultural or religious beliefs. Addressing hesitancy requires targeted education campaigns and community engagement through trusted local figures rather than top-down messaging alone.

Distribution logistics add another layer of difficulty:

• Cold chain requirements: mRNA vaccines initially required ultra-cold storage (around $-70°C$), limiting where they could be delivered
• Supply chain management: manufacturing at global scale requires coordination of raw materials, fill-finish capacity, and shipping
• Reaching underserved populations: rural areas, conflict zones, and refugee camps often lack the infrastructure for standard distribution

Global cooperation, including technology transfer and navigating intellectual property rights, remains essential for ensuring that vaccine protection reaches all populations, not just those in wealthy countries.